menu

Exploring a Screening Tool to Assess PAH Risk in SSc Patients

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Exploring a Screening Tool to Assess PAH Risk in SSc Patients

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

    Patients with systemic sclerosis (SSc) can develop PAH at any time, but a screening tool may help minimize missed diagnoses.1,2

    Please See

    INTENDED USE STATEMENT

    • Sponsored by

    • Overview

      Pulmonary arterial hypertension (PAH) is a serious complication that can develop at any time in patients with systemic sclerosis (SSc).1,2 In this video, learn about a screening tool for healthcare professionals treating SSc patients that can help routinely assess PAH risk.2

      References:

      1. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. CHEST. 2009;136(5):1211-1219.
      2. Coghlan JG, Denton CP, Grünig E, et al. DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349.

      ©2022 Actelion Pharmaceuticals US, Inc. All rights reserved. cp-257124v1 05/22

    • DETECT App's Intended Use:

      The DETECT Screening Tool for PAH-SSc was funded and developed by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company. It is limited for use by healthcare specialists who treat patients with SSc, and who are familiar with PAH as a complication of SSc. It is not intended to replace the medical or professional judgment of healthcare providers. It does not provide professional advice and should not be considered a diagnosis. Healthcare professionals using the tool should exercise clinical judgment as to the information they provide to the patient based upon the tool.

    Schedule26 Jun 2022
    Webpack App